Harmony Biosciences Holdings Aktie News

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced dosing of the first participant in a Phase 1 clinical trial of BP1.15205, an investigational, potentially best-in-class, orexin 2 receptor (OX2R) agonist being developed for the treatment of narcolepsy, idiopathic hypersomnia and other central disorders of hypersomnolence. The Phase 1 clini...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare Conference Location: Miami, FL Tuesday, December 2, 2025 8th Annual Evercore Healthcare Conference Location: Miami, FL Fireside Chat: Tuesday, December 2, 2025, at ...

Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Ami Fadia -...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increase in average number of patients of approximately 500 for the quarter, accelerating the trajectory toward blockbuster status for WAKIX in narcoleps...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over-year revenue growth These results were driven by the highest ever quarterly increase in average number of patients...

The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call trade candidates due to the liquidity and lucrativeness of the option premiums against these equities. Stocks had their biggest decline last Friday since the first half of April due to escalating trad...

Shares of Harmony Biosciences plunged Wednesday as Fragile X syndrome continued to be "undruggable" for the biotech company.

Harmony Biosciences said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial, sending its shares down 8% before the bell.